Abstract
The end-stage of Alzheimer's disease is Alzheimer's dementia, a disease that kills one in every three older adults. The disease progressively impairs cognition and functioning, and ultimately independence. With the aging of society, the prevalence of Alzheimer's dementia is increasing. The purpose of the current article is to describe a shift in drug research goals from slowing the progression of Alzheimer's dementia toward prevention of dementia through early identification of mild cognitive impairment due to Alzheimer's disease and targeted disease-modifying treatments. The first approved drug for Alzheimer's disease is aducanumab, an amyloid beta-directed monoclonal antibody that targets brain beta amyloid plaques for removal. [Journal of Psychosocial Nursing and Mental Health Services, 60(5), 11-14.].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of psychosocial nursing and mental health services
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
